Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 11,255 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Anemia, Sickle Cell
Interventions: Mindfulness-based Stress Reduction; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 30 Days to 99 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neonatal Abstinence Syndrome
Interventions: Human Milk, Standard of Care; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Up to 48 Hours
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Sickle Cell Disease
Interventions: bb1111; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 2 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more

Conditions: Genetic Predisposition
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis (CF)
Interventions: MP-376, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 16 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 39
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Lax Skin
Interventions: Renuvion APR Device; Device
Lead sponsor: Apyx Medical; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: San Diego, California • Washington D.C., District of Columbia • Montclair, New Jersey + 3 more

Conditions: Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions: GoalKeeper, Standard Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: In Utero Procedure Affecting Fetus or Newborn
Interventions: KARL STORZ fetoscope arm; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Arthritis, Gout, Fibromyalgia, Rheumatoid Arthritis, Osteoarthritis, Lupus Erythematosus, Systemic
Interventions: Phone-Based Walk With Ease; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Alexander Disease
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Deglutition Disorders
Interventions: VFSS, FEES; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 37 Weeks and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Labor, Premature
Interventions: Magnesium, Nifedlipine; Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Lipodystrophy
Interventions: Not listed
Lead sponsor: PatientCrossroads; Industry
Eligibility: Not listed
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: Sit to stand test; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 35 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Over-weight, Prader-Willi Syndrome
Interventions: ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension; Drug
Lead sponsor: Zafgen, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase + immune globulin intravenous; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas

Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions: Intravenous and Intranasal BMSC; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Traumatic Birth
Interventions: Intravenous (IV) hydrocortisone; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Congenital Heart Disease, Congenital Heart Defect
Interventions: Peer Health Coaching; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 26 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dermatitis, Atopic Dermatitis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more

Conditions: Skin Laxity
Interventions: L.M.X.4.® cream, A placebo cream, Ulthera System Treatment; Drug · Other · Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

MBSR for Pain Catastrophizing in SCD

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Phone-Based Based Walk With Ease Program for Adults With Arthritis

Evaluation of Outcome Metrics in Alexander Disease

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Comparing FEES to VFSS in Diagnosing Laryngeal Penetration and Aspiration in Infants in the NICU

Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population

Lipodystrophy Connect Patient Registry

Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Neurologic Stem Cell Treatment Study

Glucocorticoid Administration After Traumatic Birth

Peer Coaching Intervention in Young Adults With Congenital Heart Disease

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment